Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule ...
BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-202511.1-month median PFS in heavily pre-treated ...
Clinically meaningful activity was observed in 57 patients at 400 mg BID fed, including 11.1-month median PFS and mutation-subtype–agnostic benefit across kinase versus nonkinase PIK3CA variants.
Data from the ongoing PIKture-01 trial is expected to be announced in March 2026; continued enrollment in breast cancer triplet combinations ...
Detailed price information for Bridgebio Oncology Therapeutics Inc (BBOT-Q) from The Globe and Mail including charting and trades.
RLY-2608’s pan-mutant inhibition has the potential to address over 100,000 patients per year in the U.S. The data presented at the conference show that in preclinical models, RLY-2608 preferentially ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. (ENSEM), a pioneering drug discovery and development company that leverages its unique Kinetic Ensemble® platform to advance innovative small ...
LA JOLLA, CA— To design drugs that stall the growth of aggressive cancers, it helps to know the structures of the proteins that are revving the cancers’ engines. In a series of three papers published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results